Charité – Universitätsmedizin Berlin at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Charité – Universitätsmedizin Berlin takes part in 6 sessions at ESMO 2026 in Madrid. Its program spans immune and targeted therapy, from a PRAME-directed T-cell therapy to KRAS G12C-mutant lung cancer and molecular profiling in metastatic colorectal cancer. Other sessions cover biomarkers in HPV-related head and neck cancer, durvalumab with BCG in high-risk bladder cancer and small cell neuroendocrine genitourinary tumours.
| Organization | ESMO 2026 Attendance |
|---|---|
Charité – Universitätsmedizin Berlin Berlin, Germany | |
University hospital and medical faculty shared by Freie Universität Berlin and Humboldt-Universität zu Berlin, in Berlin, Germany. | Abstract Fri Oct 23 13:30–13:40 Chair Sat Oct 24 08:30–10:00 Challenges in the treatment approach of HPV-related head and neck cancers Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 09:30–09:50 Biomarkers to tailor treatment and monitor disease Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 10:15–10:20 Satellite Sat Oct 24 13:25–13:45 KRAS G12C in Advanced NSCLC: Progress Made, Gaps Remaining Lung & thoracic cancers Talk Sat Oct 24 15:00–15:15 Small cell neuroendocrine tumours Genitourinary cancers Satellite Sun Oct 25 13:40–13:55 The role of molecular profiling in mCRC Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:55–14:25 From the clinic: Applying precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology |
Instantly find 20 buyers from Charité – Universitätsmedizin Berlin
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction